Table 5.
Study | Measurement | Follow-Up (mo) | Results |
Wadhwa P et al (2007)52 | DMSA, DTPA, EDC | 3 | No change in GFR or split renal function |
No new cortical scars | |||
Mahmud M, Zaidi Z (2004)105 | DMSA | 1.5 | No new cortical scars |
Desai MR et al (2004)106 | DMSA, Serum creatinine | 3–6, 12 | No new cortical scars |
No change in creatinine | |||
Mor Y et al (1997)108 | DMSA, DTPA, MAG3 | 23 | No decline in function |
Dawaba MS et al (2004)109 | DMSA, DTPA | 40 | Significant increase in GFR |
No new cortical scars | |||
Samad L et al (2007)107 | DMSA | 3.6 | New cortical defects in 5% of patients |
EDC, 99mTc-ethylene dicystine; DMSA, dimercaptosuccinic acid; DTPA, 99mTc-diethylenetriaminepentaacetic acid; GFR, glomerular filtration rate; MAG3, 99mTc-mercaptoacetyltriglycine.